Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4898-4905

  Pollack, Ian F ^a,b,c   Erff, Melanie ^a,b,c   Bom, David ^c   Burke, Thomas G ^d   Strode, J Thompson ^d   Curran, Dennis P ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DB 67; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; SILATECAN DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL DIVISION; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; GENES, P53; GLIOMA; HUMANS; MICE; MICE, NUDE; MUTATION; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033213921     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Devaux, B. C., O'Fallon, J. R., and Kelly, P. J. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J. Neurosurg., 78: 767-775, 1993.
2. Finlay, J. L., Boyett, J. M., Yates, A. J., Wisoff, J. H., Milstein, J. M., Geyer, J. R., Bertolone, S. J., McGuire, P., Cherlow, J. M., Tefft, M., Turski, P. A., Wara, W. M., Edwards, M., Sutton, L. N., Berger, M. S., Epstein, F., Ayers, G., Allen, J. C., and Packer, R. J. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J. Clin. Oncol., 13: 112-123, 1995.
3. Nazzaro, J. M., and Neuwelt, E. A. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J. Neurosurg., 73: 331-344, 1990.
4. Pollack, I. F. Current concepts: brain tumors in children. N. Engl. J. Med., 331: 1500-1507, 1994.
5. D'Arpa, P., Beardmore, C., and Lui, F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
6. Takimoto, C. H., and Arbuck, S. G. Clinical status and optimal use of topotecan. Oncology, 11: 1635-1657, 1997.
7. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer xenografts. Science (Washington DC), 246: 1046-1048, 1989.
8. Husain, I., Mohler, J. L., Seigler, H. F., and Besterman, J. M. Elevation of topoisomerase messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54: 539-546, 1994.
9. Savaraj, N., Xu, R., Wu, C. J., Landy, H., Chua, L., Solomon, J., and Feun, L. Correlation of in vitro antitumor activity of irinotecan and topoisomerase I activity and levels in brain tumor. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 14: A1610, 1995.
10. Hsiang, Y-H., and Lui, L. F. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
11. Potmesil, M. Camptothecins. From bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
12. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., and Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J. Natl. Cancer Inst., 83: 1164-1168, 1991.
13. Rowinsky, E., Grochow, L., Hendricks, C., Sartorius, S., Ettinger, D., McGuire, W., Forastiere, A., Hurowitz, L., Easter, V., and Donehower, R. Phase I and pharmacokinetic study of topotecan (SK & F 104864): a novel topoisomerase I inhibitor. Proc. Am. Soc. Clin. Oncol., 10: 93, 1991.
14. Lamond, J. P., Mehta, M. P., and Boothman, D. A. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and irradiation. J. Neuro-Oncol., 30: 1-6, 1996.
15. Tubergen, D., Pratt, C., Stewart, C., and Vietti, T. Phase I study of topotecan in children with refractory solid tumors: a Pediatric Oncology Group study. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 13: A463, 1994.
16. Blaney, S. M., Phillips, P. C., Packer, R. J., Heideman, R. L., Berg, S. L., Adamson, P. C., Allen, J. C., Sallan, S. E., Jakacki, R. I., Lange, B. J., Reaman, G. H., Horowitz, M. E., Poplack, D. G., and Balis, F. M. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer (Phila.), 78: 527-531, 1996.
17. Burch, P. A., Novotony, P. J., Bernath, A. M., Cascino, T. L., Addo, F. K., Keppen, M. D., Kugler, J. W., and Buckner, J. C. A North Central Cancer Treatment Group Phase II trial of topotecan in relapsed gliomas. Proc. Annu. Meet. Am. Assoc. Cancer Res., 37: A1164, 1996.
18. Kyritsis, A., Newlands, E. S., Brock, C. S., Gleason, M., Jaeckle, K., Levin, V., Bower, M., Evans, H., Dave, G., Dewitte, M., and Yung, W. Phase II trial of topotecan (T) as a continuous intravenous infusion (CIV) in patients (pts) with high-grade gliomas. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 16: A1404, 1997.
19. Macdonald, D., Caimcross, G., Stewart, D., Forsyth, P., Sawka, C., Wainman, N., and Eisenhauer, E. Phase II study of topotecan in patients with recurrent malignant glioma. National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol., 7: 205-207, 1996.
20. Baker, S. D., Heideman, R. L., Crom, W. R., Kuttesch, J. F., Gajjar, A., and Stewart, C. F. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother. Pharmacol., 37: 195-202, 1996.
21. Mi, Z., Malak, H., and Burke, T. G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry, 34: 13722-13728, 1995.
22. Verweij, L., Lund, B., Beijnen, J., Planting, A., de Boer-Dennert, M., Koier, I., Rosing, H., and Hansen, H. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol., 4: 673-678, 1993.
23. Houghton, P. J., Stewart, C. F., Thompson, J., Santana, V. M., Furman, W. L., and Friedman, H. S. Preclinical and clinical results with irinotecan. Extending principles learned in model systems to clinical trials design. Oncology, 12 (Suppl. 6). 84-93, 1998.
24. Reid, J., Buckner, J., Schaaf, L., Novotny, P., Wright, K., Kimmel, D., and Miller, L. Pharmacokinetics of irinotecan (CPT-11) in recurrent glioma patients: results of an NCCTG phase II trial. Proc. Am. Soc. Clin. Oncol., 18: 141a, 1999.
25. Filka, E., Nelson, G., Friedman, H., Kabbinavar, F., Miller, L., Menco, H., and Cloughesy, T. Intrapatient dose escalation of irinotecan in patients with recurrent malignant glioma receiving anticonvulsants. Proc. Am. Soc. Clin. Oncol., 18: 144a, 1999.
26. Cloughesy, T. F., Nelson, G., Falka, E., Kabbinavar, F., Friedman, H. S., Selch, M., and Miller, L. Irinotecan treatment for recurrent malignant glioma using an every three week regimen. Proc. Am. Soc. Clin. Oncol., 18: 144a, 1999.
27. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
28. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., and Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of undine diphosphate glucuronosyltransferase isoform 1A1 in the glucoronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Investig., 101: 847-854, 1998.
29. Rivory, L. P., Haaz, M. C., Canal, P., Lokiec, F., Armand, J. P., and Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials. Clin. Cancer Res., 3: 1261-1266, 1997.
30. Josien, H., Bom, D., Curran, D. P., Zheng, Y-H., and Chou, T. C. 7-Silylcamptothecins (silatecans): a new family of camptothecin antitumor agents. Bioorgan. Med. Chem. Lett., 7: 3189-3194, 1997.
31. Josien, H., Ko, S. B., Bom, D., and Curran, D. P. A general synthetic approach to the (20S)-camptothecin family of antitumor agents by a regiocontrolled cascade radical cyclization or aryl isonitriles. Chem. Eur. J., 4: 67-83, 1998.
32. Curran, D. P., and Lui, H. New 4 + 1 radical annulations. A formal total synthesis of ±-camptothecin. J. Am. Chem. Soc., 114: 5863-5864, 1992.
33. Curran, D. P., Lui, H., Josien, H., and Ko, S. B. Tandem radical reactions of isonitriles with 2-pyridonyl and other aryl radicals: scope and limitations, and a first generation synthesis of (+/-)-camptothecin. Tetrahedron, 52: 11385-11404, 1996.
34. Riss, T. L., and Moravec, R. A. Comparison of MTT, XTT, and a novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays. Mol. Biol. Cell 3 (Suppl.): 184a, 1992.
35. Burke, T. G., and Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem., 37: 40-46, 1994.
36. Burke, T. G., Mi, Z., Jiang, Y., and Munshi, C. B. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm. Sci., 84: 518-519, 1995.
37. Warner, D. L., and Burke, T. G. A simple and versatile HPLC method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J. Chromatogr. B Biomed. Appl., 691: 161-171, 1997.
38. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., and Sim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888-3890, 1966.
39. Wall, M. E. Alkaloids with antitumor activity. In: K. Mothes, K. Schreiber, and H. R. Schutte (eds.), International Symposim on Biochemistry and Physiology of the Alkaloids, p. 77. Berlin: Academie-Verlag, 1969.
40. Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Tele, C., Moore, L., Truesdale, A., Leither, P., and Besterman, J. M. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem., 36: 2689-2701, 1993.
41. Fassberg, J., and Stella, V. J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci., 81: 676-684, 1992.
42. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47: 5944-5947, 1987.
43. Nakatsu, S., Kondo, S., Kondo, Y., Yin, D., Peterson, J. W., Kaakaji, R., Morimura, T., Kikuchi, H., Takeuchi, J., and Barnett, G. H. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother. Pharmacol., 39: 417-423, 1997.
44. Tsuruo, T., Matsuzaki, M., Saito, H., and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21: 71-74, 1988.
45. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., and Hertzberg, R. P. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
46. Valenti, M., Nieves-Neira, W., Kohlhagen, G., Kohn, K. W., Wall, M. E., Wani, M. C., and Pommier, Y. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol. Pharmacol., 52: 82-87, 1997.
47. Burke, T. G., and Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem., 212: 285-287, 1983.
48. Mi, Z., and Burke, T. G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry, 33: 10325-10336, 1994.
49. Burke, T. G., Staubus, A. E., Mishra, A. K., and Malak, H. Liposomal stabilization of camptothecin's lactone ring. J. Am. Chem. Soc., 114: 8318-8319, 1992.
50. Burke, T. G., Mishra, A. K., Wani, M., and Wall, M. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32: 5352-5364, 1993.
51. Phillips, P. C., Janss, A., Kaufman, S. H., Levow, C., Yao, Y., and Colvin, O. M. Topoisomerase I inhibitor schedule dependent activity and determinants of cytotoxicity in human brain tumor cell lines. Proc. Annu. Meet. Am. Assoc. Cancer Res., 35: A2161, 1994.
52. Pollina, J., Ciesielski, M., Lis, A., Castiglia, G., Greenberg, S., Fenstermaker, R., and Plunkett, R. Efficacy and distribution of intratumoral topotecan in a nude rat glioma model and the Rhesus monkey. Proc. Annu. Meet. Am. Assoc. Cancer Res., 38: A2046, 1997.
53. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
54. Hare, C. B., Elion, G. B., Houghton, P. J., Houghton, J. A., Keir, S., Marcelli, S. L., Bigner, D. D., and Friedman, H. S. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol., 39: 187-191, 1997.
55. Coggins, C. A., Elion, G. B., Houghton, P. J., Hare, C. B., Keir, S., Colvin, O. M., Bigner, D. D., and Friedman, H. S. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol., 41: 485-490, 1998.